Adverse effects Timing of outcome assessment: end of treatment · patients with borderline personality disorder
Psychotherapy showed no clear difference in adverse effects Timing of outcome assessment: end of treatment compared with treatment‐as‐usual (low certainty).
1 finding from 1 review
BPD symptom severity Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · patients with borderline personality disorder
1 finding from 1 review
Deliberate self‐harm · patients with borderline personality disorder
1 finding from 1 review
Mobility · children with cerebral palsy classified within GMFCS Levels I to III between 5 and 19 years of age
1 finding from 1 review
Mobility · children with cerebral palsy classified within GMFCS Levels I to V and between 3 and 18 years of age
1 finding from 1 review
Activity Gross motor function · children with cerebral palsy classified within GMFCS Levels I to V and between 3 and 18 years of age
1 finding from 1 review
Adverse events 12 months postintervention · children with cerebral palsy classified within GMFCS Levels I to V and between 3 and 18 years of age
1 finding from 1 review
Participation · children with cerebral palsy classified within GMFCS Levels I to V and between 3 and 18 years of age
1 finding from 1 review
Quality of life Measured by: PedsQOL‐CP score (range from 0 to 100; higher scores = better quality of life) Timing of outcome assessment: change scores from baseline to 12 weeks · children with cerebral palsy classified within GMFCS Levels I to V and between 3 and 18 years of age
1 finding from 1 review
Activity Gross motor function · children with cerebral palsy classified within GMFCS Levels I to IV and between 4 and 18 years of age
1 finding from 1 review
Participation · children with cerebral palsy classified within GMFCS Levels I to IV and between 4 and 18 years of age
1 finding from 1 review
Activity Gross motor function · children with cerebral palsy classified within GMFCS Levels I to III between 5 and 19 years of age
1 finding from 1 review
Adverse events 12 months postintervention · children with cerebral palsy classified within GMFCS Levels I to III between 5 and 19 years of age
1 finding from 1 review
Mobility · children with cerebral palsy classified within GMFCS Levels I to III and between 3 and 12 years of age
1 finding from 1 review
Activity Gross motor function · children with cerebral palsy classified within GMFCS Levels I to III and between 3 and 12 years of age
1 finding from 1 review
Participation · children with cerebral palsy classified within GMFCS Levels I to III and between 3 and 12 years of age
1 finding from 1 review
Acceptability (number of participants lost to post‐treatment assessment) · children and adolescents with anxiety disorders
CBT showed no clear difference in acceptability (number of participants lost to post‐treatment… compared with treatment (low certainty).
1 finding from 1 review
Acceptability (number of participants lost to post‐treatment assessment) · children and adolescents with anxiety disorders
CBT showed no clear difference in acceptability (number of participants lost to post‐treatment… compared with attention control (low certainty).
1 finding from 1 review
Acceptability (number of participants lost to post‐treatment assessment) · children and adolescents with anxiety disorders
CBT showed no clear difference in acceptability (number of participants lost to post‐treatment… compared with waitlist (low certainty).
1 finding from 1 review
Acceptability (number of participants lost to post‐treatment assessment) · children and adolescents with anxiety disorders
CBT showed no clear difference in acceptability (number of participants lost to post‐treatment… compared with alternative treatment (low certainty).
1 finding from 1 review